phrykt

iBio, Inc. (IBIO): who owns it and who trades it

As of Nov 16, 2026, IBIO insiders reported 4 purchases worth $98.1K in the last 12 months. The largest buyer was Felipe Duran (CFO), with $50.2K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling iBio

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IBIO

55 funds and institutions reported IBIO shares worth $60.8M at the end of Q2 2026, about 70% of the company. The largest holder is Affinity Asset Advisors, LLC with 8.1%.

Funds and institutions (13F) 70%Everyone else 30%

10 largest owners, by share of the company

Affinity Asset Advisors, LLC8.1%
Cormorant Asset Management, LP7.2%
Silverarc Capital Management, LLC7.1%
Vestal Point Capital, LP5.2%
Vanguard Capital Management LLC4.2%
Frazier Life Sciences Management, L.P.3.9%
Ensign Peak Advisors, Inc3.7%
Woodline Partners LP3.6%
Millennium Management LLC3.3%
Citadel Advisors LLC2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Affinity Asset Advisors, LLC4.01M8.07%$7M+29%
Cormorant Asset Management, LP3.57M7.19%$6.2MNew
Silverarc Capital Management, LLC3.52M7.09%$6.2M+1458%
Vestal Point Capital, LP2.60M5.23%$4.5MNew
Vanguard Capital Management LLC2.10M4.22%$3.7M+93%
Frazier Life Sciences Management, L.P.1.95M3.93%$3.4MNo change
Ensign Peak Advisors, Inc1.83M3.69%$3.2MNew
Woodline Partners LP1.78M3.58%$3.1MNew
Millennium Management LLC1.65M3.32%$2.9M+7%
Citadel Advisors LLC1.38M2.79%$2.4M+45%
Balyasny Asset Management L.P.1.17M2.36%$2M+16%
Bank of America Corp1.12M2.26%$2M+286%
Ikarian Capital, LLC957,0621.93%$1.7MNo change
Sio Capital Management, LLC904,2681.82%$1.6MNo change
Marshall Wace, LLP904,1321.82%$1.6M+46%
Geode Capital Management, LLC500,8161.01%$877K+29%
Walleye Capital LLC500,3751.01%$876K+29%
Squarepoint Ops LLC498,8721.00%$873KNew
Noesis Capital Mangement Corp405,0000.82%$709K+30%
Two Sigma Investments, LP400,6670.81%$701K-2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IBIO insiders reported $98.1K of open-market purchases and $0 of sales.

Purchases, 12 months
$98.1K
4 trades, 3 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Mar 26, 2026
Filed Mar 27, 2026

Purchases and sales by month

$98.1K$98.1KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 26, 2026Marc BanjakChief Legal OfficerPurchase12,500$1.64$20.5KForm 4
Mar 26, 2026Marc BanjakChief Legal OfficerPurchase1,434$1.76$2.5KForm 4
Mar 19, 2026Felipe DuranCFOPurchase24,835$2.02$50.2KForm 4
Mar 19, 2026Martin BrennerDirectorPurchase12,336$2.02$24.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Felipe DuranChief Financial Officer$50.2K–Mar 19, 2026
Martin BrennerSee Remarks, Director$24.9K–Mar 19, 2026
Marc BanjakChief Legal Officer$23K–Mar 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IBIO short interest

Moderate short interest. 6.3% of IBIO shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 18%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.03M IBIO shares were sold short, 6.3% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 563,738 shares, buying them all back would take about 7.2 trading days (days to cover).

Shares short, % of all shares

6.27%May 15Oct 3011.6%

Days to cover

7.2May 15Oct 3012.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.03M6.27%+8%563,7387.2
Oct 15, 20263.73M5.80%-11%1.06M3.5
Sep 30, 20264.20M6.53%-15%681,5656.2
Sep 15, 20264.94M7.68%-5%494,35110.0
Aug 31, 20265.20M8.09%+4%895,0385.8
Aug 14, 20265.03M10.12%-2%452,02611.1
Jul 31, 20265.11M10.28%-5%732,7577.0
Jul 15, 20265.38M10.84%+15%1.34M4.0
Jun 30, 20264.69M9.45%+25%924,9575.1
Jun 15, 20263.76M7.56%-0%780,1494.8
May 29, 20263.76M7.57%+10%781,8854.8
May 15, 20263.41M6.86%-0%958,0813.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

iBio company events

iBio filed 18 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 19, 2026LeadershipIBio, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  3. Oct 13, 2026AnnouncementThe Company issued a press release highlighting preclinical body-composition data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Filing
  4. Sep 14, 2026AnnouncementThe Company has updated its corporate presentation for use in meetings with investors, analysts and others. Filing
  5. Aug 28, 2026ResultsReleased financial results. Filing
  6. Aug 4, 2026LeadershipMolly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. Filing
  7. Jul 17, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 5.08. ​ Item 8.01. Filing
  8. Jul 1, 2026AnnouncementThe Company issued a press release announcing new preclinical data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Filing
  9. May 12, 2026ResultsReleased financial results. Filing
  10. May 8, 2026LeadershipThe Board of Directors of iBio, Inc., following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026, and to serve until the Company’s 2028 annual… Filing
  11. Apr 17, 2026AnnouncementAmended an earlier report. Of the Current Report on Form 8-K it filed with the Securities and Exchange Commission on April 8, 2026 to correct a typographical error contained therein regarding the date that the Series G warrants to purchase up to 35,770,000 shares of the Company’s common stock, par value $0.001 per share will… Filing
  12. Apr 8, 2026AnnouncementThe Company issued a press release announcing that it received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling the initiation of a first-in-human clinical trial of IBIO-600 in… Filing
  13. Mar 9, 2026AnnouncementThe Company issued a press release announcing preclinical data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Filing
  14. Feb 27, 2026AgreementIBio, Inc., a Delaware corporation, entered into an Open Market Sale Agreement SM with Jefferies LLC providing for the sale by the Company of its shares of common stock, par value $0.001 per share, from time to time, through or to Jefferies in an at-the-market offering program as set forth in the… Filing
  15. Feb 10, 2026ResultsReleased financial results. Filing
  16. Jan 12, 2026AgreementIBio, Inc., a Delaware company, entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC an… Filing
  17. Nov 21, 2025VoteReported shareholder vote results. Filing
  18. Nov 17, 2025AnnouncementThe Company has updated its corporate presentation for use in meetings with investors, analysts and others. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

iBio financials

Famous investors that hold IBIO

3 of the 50 well-known investors we track reported holding IBIO in their latest 13F filing. The largest position is Israel Englander's, worth $1.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.42M$1.7M0.0%-14%
Jim Simons · Renaissance TechnologiesQ3 2026688,400$812K0.0%+239%
Ken Griffin · Citadel AdvisorsQ3 2026666,171$786K0.0%-52%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named IBIO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Frazier Life Sciences Public Fund, L.P.13G/A3.0%
Nov 16, 2026Frazier Life Sciences Public Fund, L.P.13G/A3.0%
Oct 14, 2026Coastlands Capital LP13G9.7%
Oct 14, 2026Coastlands Capital LP13G9.7%

Questions about iBio, Inc. (IBIO) stock

Who owns the most IBIO stock?

The largest reported owner of iBio, Inc. (IBIO) is Affinity Asset Advisors, LLC, with 8.1% of the company. In total, 55 funds and institutions reported holding IBIO at the end of Q2 2026, together about 70% of the shares. See the largest owners.

Are IBIO insiders buying or selling?

In the last 12 months, IBIO insiders reported 4 open-market purchases worth $98.1K and no sales. The latest trade was on Mar 26, 2026. See every trade.

What is the short interest in IBIO?

As of Oct 30, 2026, 4.03M IBIO shares were sold short, 6.3% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 563,738 shares, buying them all back would take about 7.2 trading days (days to cover). See the history.

Which famous investors hold IBIO?

3 of the 50 well-known investors we track reported IBIO in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $1.7M. See all holders.

Executive pay

iBio's chief executive was paid a total of $2.1M for the year ended Jun 30, 2026, up 42% from $1.5M the year before. In the last 12 months, iBio's executives and directors bought $98.1K of stock on the open market and sold none.

Chief executive, total pay$2.1MYear ended Jun 30, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.